Green tea and the risk of prostate cancer: A systematic review and meta-analysis

Medicine (United States)

Volumn 96, Issue 13, 2017, Pages

  Guo, Yuming ^a   Zhi, Fan ^b   Chen, Ping ^a   Zhao, Keke ^a   Xiang, Han ^a   Mao, Qi ^a   Wang, Xinghuan ^a   Zhang, Xinhua ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b China   (China)

Author keywords

Dose response; Green tea; Green tea catechins; Meta analysis; Prostate cancer

Indexed keywords

CATECHIN; EPIGALLOCATECHIN GALLATE; TEA;

CANCER INCIDENCE; CANCER RISK; CLINICAL EFFECTIVENESS; HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; TEA; CARCINOMA; MALE; PHYTOTHERAPY; PROSTATIC NEOPLASMS;

CARCINOMA; CATECHIN; HUMANS; MALE; PHYTOTHERAPY; PROSTATIC NEOPLASMS; TEA;

EID: 85016924906     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000006426     Document Type: Review

References (46)

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
2. Canby-Hagino ED, Thompson IM. Mechanisms of disease: prostate cancer - a model for cancer chemoprevention in clinical practice. Nat Clin Pract Oncol 2005;2:255-61.
3. Butt MS, Ahmad RS, Sultan MT, et al. Green tea and anticancer perspectives: updates from last decade. Crit Rev Food Sci Nutr 2015; 55:792-805.
4. Chen P, Zhang W, Wang X, et al. Lycopene and risk of prostate cancer: a systematic review and meta-analysis. Medicine 2015;94:e1260.
5. Higdon JV, Frei B. Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr 2003; 43:89-143.
6. Bettuzzi S, Brausi M, Rizzi F, et al. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006;66:1234-40.
7. Chuu CP, Chen RY, Kokontis JM, et al. Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells. Cancer Lett 2009;275:86-92.
8. Yang JG, Yu HN, Sun SL, et al. Epigallocatechin-3-gallate affects the growth of LNCaP cells via membrane fluidity and distribution of cellular zinc. J Zhejiang Univ Sci B 2009;10:411-21.
9. Sartor L, Pezzato E, Donà M, et al. Prostate carcinoma and green tea: (-) epigallocatechin-3-gallate inhibits inflammation-triggered MMP-2 activation and invasion in murine TRAMP model. Int J Cancer 2004; 112:823-9.
10. Liao S, Umekita Y, Guo J, et al. Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Cancer Lett 1995;96:239-43.
11. Kurahashi N, Sasazuki S, Iwasaki M, et al. Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am J Epidemiol 2008;167:71-7.
12. Jian L, Lee AH, Binns CW. Tea and lycopene protect against prostate cancer. Asia Pac J Clin Nutr 2007;16(Suppl 1):453-7.
13. Montague JA, Butler LM, Wu AH, et al. Green and black tea intake in relation to prostate cancer risk among Singapore Chinese. Cancer Causes Control 2012;23:1635-41.
14. Kikuchi N, Ohmori K, Shimazu T, et al. No association between green tea and prostate cancer risk in Japanese men: the Ohsaki Cohort Study. Br J Cancer 2006;95:371-3.
15. Allen NE, Sauvaget C, Roddam AW, et al. A prospective study of diet and prostate cancer in Japanese men. Cancer Causes Control 2004;15: 911-20.
16. Zheng J, Yang B, Huang T, et al. Green tea and black tea consumption and prostate cancer risk: an exploratory meta-analysis of observational studies. Nutr Cancer 2011;63:663-72.
17. Lin YW, Hu ZH, Wang X, et al. Tea consumption and prostate cancer: an updated meta-analysis. World J Surg Oncol 2014;12:38.
18. Fei X, Shen Y, Li X, et al. The association of tea consumption and the risk and progression of prostate cancer: a meta-analysis. Int J Clin Exp Med 2014;7:3881-91.
19. Yu F, Jin Z, Jiang H, et al. Tea consumption and the risk of five major cancers: a dose-response meta-analysis of prospective studies. BMC Cancer 2014;14:197.
20. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. 2011. www.ohri.ca/programs/clinical-epidemiology/oxford.asp. [Accessed April 16, 2016].
21. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987;9:1-30.
22. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 1992;135:1301-9.
23. Orsini N, Li R, Wolk A, et al. Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. Am J Epidemiol 2012;175:66-73.
24. Yoshimura I. The effect of measurement error on the dose-response curve. Environ Health Perspect 1990;87:173-8.
25. Berroukche A, Bendahmane M, Kandouci BA. Association of diet with the risk of prostate cancer in Western Algeria. Oncologie 2012;14: 674-8.
26. Sonoda T, Nagata Y, Mori M, et al. A case-control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet. Cancer Sci 2004;95:238-324.
27. Jian L, Xie LP, Lee AH, et al. Protective effect of green tea against prostate cancer: a case-control study in southeast China. Int J Cancer 2004;108:130-5.
28. Kumar NB, Pow-Sang J, Egan KM, et al. Randomized, placebocontrolled trial of green tea catechins for prostate cancer prevention. Cancer Prev Res (Phila) 2015;8:879-87.
29. Brausi M, Rizzi F, Bettuzzi S. Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. Eur Urol 2008;54:472-3.
30. Kapetanovic IM, Crowell JA, Krishnaraj R, et al. Exposure and toxicity of green tea polyphenols in fasted and non-fasted dogs. Toxicology 2009;260:28-36.
31. Johnson R, Bryant S, Huntley AL. Green tea and green tea catechin extracts: an overview of the clinical evidence. Maturitas 2012;73:280-7.
32. Asghar Z, Masood Z. Evaluation of antioxidant properties of silymarin and its potential to inhibit peroxyl radicals in vitro. Pak J Pharm Sci 2008;21:249-54.
33. Anesini C, Ferraro GE, Filip R. Total polyphenol content and antioxidant capacity of commercially available tea (Camellia sinensis) in Argentina. J Agric Food Chem 2008;56:9225-9.
34. Ren F, Zhang S, Mitchell SH, et al. Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene 2000;19:1924-32.
35. Harper CE, Patel BB, Wang J, et al. Epigallocatechin-3-Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action. Prostate 2007;67:1576-89.
36. Liao S, Hiipakka RA. Selective inhibition of steroid 5 alpha-reductase isozymes by tea epicatechin-3-gallate and epigallocatechin-3-gallate. Biochem Biophys Res Commun 1995;214:833-8.
37. Kao YH, Hiipakka RA, Liao S. Modulation of endocrine systems and food intake by green tea epigallocatechin gallate. Endocrinology 2000; 141:980-7.
38. Thomas F, Patel S, Holly JM, et al. Dihydrotestos-terone sensitises LNCaP cells to death induced by epigallocatechin-3-Gallate (EGCG) or an IGF-I receptor inhibitor. Prostate 2009;69:219-24.
39. Kazi A, Smith DM, Zhong Q, et al. Inhibition of bcl-x(l) phosphorylation by tea polyphenols or epigallocatechin-3-gallate is associated with prostate cancer cell apoptosis. Mol Pharmacol 2002;62:765-71.
40. Bettuzzi S, Davalli P, Astancolle S, et al. Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens. Cancer Res 2000; 60: 28-34.
41. Leskov KS, Klokov DY, Li J, et al. Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem 2003;278:11590-600.
42. Pezzato E, Sartor L, Dell'Aica I, et al. Prostate carcinoma and green tea: PSA-triggered basement membrane degradation and MMP-2 activation are inhibited by (-)epigallocatechin-3-gallate. Int J Cancer 2004;112: 787-92.
43. Siddiqui IA, Malik A, Adhami VM, et al. Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene 2008;27:2055-63.
44. Adhami VM, Siddiqui IA, Ahmad N, et al. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res 2004;64: 8715-22.
45. Siddiqui IA, Zaman N, Aziz MH, et al. Inhibition of CWR22Rnu1 tumor growth and PSA secretion in athymic nude mice by green and black teas. Carcinogenesis 2006;27:833-9.
46. Inoue-Choi M, Yuan JM, Yang CS, et al. Genetic association between the COMT genotype and urinary levels of tea polyphenols and their metabolites among daily green tea drinkers. Int J Mol Epidemiol Genet 2010;1:114-23.